Beyond the hype: examining the therapeutic potential of psychedelic microdosing through the lens of experimental control and evidence
O. Mallon1
1Imperial College London, Department of Brain Sciences, London, United Kingdom

Background: The practice of psychedelic microdosing has grown outside of the medical realm from a community of self-medicating users who endorse improvements in cognitive functioning and mental health. The breadth and strength of this advocacy has led many to replace traditional psychotropic medication and well-being support with an under researched practice. This represents a divide between public perceptions and evidence-based medicine, which raises due concern among healthcare practitioners who lack the information to responsibly advise patients on the suitability and risks of microdosing.
Aims & Objectives: The Tree of Evidence (ToE) aims to bridge this clinical knowledge gap by mapping all empirical findings on microdosing along a hierarchy of scientific rigour, assessing the extent to which current research supports, or struggles to support, its purported benefits.
Method: A PRISMA-guided systematic review identified 48 eligible studies on psychedelic microdosing published before November 2024. Human trials using sub-perceptual doses of classic psychedelics were included, excluding studies where microdoses were active placebos in macrodose research. Quality assessment following a GRADE-based model was used to rank studies, with findings mapped into a visual hierarchy of evidence.
Results: 

The ToE visually maps findings from microdosing studies using pie charts that summarize outcomes as beneficial (green), adverse (red), or neutral (white), and indicates the proportion of significant effects. Pie charts are organized by research categories (affective, cognitive, psychological, somatic) and experimental variables (drug, dose, outcome timing) to allow comparison between and illustrate how study design influences results. Studies are tiered based on design rigor, with higher tiers reflecting lower risk of bias. Together, the ToE forms a pyramid with the most robust research at the top and higher-risk studies at the base. Findings in lower tiers, dominated by uncontrolled designs, show predominantly green (beneficial) effects. In contrast, placebo-controlled studies in upper tiers display pies with muted or white colors, reflecting a lack of significant beneficial outcomes. This figure provides a clear visual contrast between perceived and pharmacologically validated effects, highlighting the impact of placebo control on reported outcomes. The ToE summarises findings from individual microdosing studies into pie charts, mapped across research categories and experimental levels, to demonstrate the direction and strength of evidence as experimental control (measured using a risk of bias evaluation) is increased.
Discussion & Conclusions: The ToE reveals that while self-reported benefits from microdosing are prevalent, the inclusion of a placebo-control leads to a substantial reduction in significant effects and increased bi-directionality. When controlled findings are presented at face value rather than relative to placebo, they mirror the overwhelmingly beneficial (green) effects reported in anecdotal and observational studies. This pattern visually highlights that although microdosing is widely perceived as beneficial, current evidence does not conclusively attribute these effects to its pharmacological action. Given the growing media attention and increasing public interest in microdosing as an alternative to traditional medications, careful communication is needed to temper sensationalized claims of therapeutic efficacy. Promoting rigorous research in clinical populations is essential to ensure that personal anecdotes are not mistaken for scientific validation.
In sessions